Evidence map›Paper›PMID 30057145›Full record

ArticleCancer cell2018

Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.

Masao Nakagawa, Arthur L Shaffer, Michele Ceribelli, Meili Zhang, George Wright, Da Wei Huang, Wenming Xiao, John Powell, Michael N Petrus, Yibin Yang and 17 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 120 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. BATF3 regulates differentiation of CD8Life science alliance · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. JunB-HBZ nuclear translocation by TGF-β is a key driver in HTLV-1-mediated leukemogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  17. Review
  18. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  19. Review
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 2 countries.

Masao NakagawaLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido 060-8638, Japan.
Arthur L ShafferLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Michele CeribelliLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Division of Pre-Clinical Innovation, NCATS, NIH, Bethesda, MD 20892, USA.
Meili ZhangLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
George WrightBiometric Research Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Da Wei HuangLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Wenming XiaoLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Division of Bioinformatics and Biostatistics, NCTR/FDA, Jefferson, AR 72079, USA.
John PowellBioinformatics and Molecular Analysis Section, Division of Computational Bioscience, Center for Information Technology, National Institutes of Health, Bethesda, MD 20892, USA.
Michael N PetrusLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Yibin YangLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
James D PhelanLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Holger KohlhammerLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Sigrid P DuboisLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Hee Min YooLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Emmanuel BachyLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Daniel E WebsterLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Yandan YangLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Weihong XuLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Xin YuLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Hong ZhaoLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Bonita R BryantLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Joji ShimonoDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido 060-8638, Japan.
Takashi IshioDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Hokkaido 060-8638, Japan.
Michiyuki MaedaInstitute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan.
Patrick L GreenCenter for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA.
Thomas A WaldmannLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: tawald@helix.nih.gov.
Louis M StaudtLymphoid Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: lstaudt@mail.nih.gov.
National Cancer Institute · USHokkaido University · JPKyoto University · JPNational Institutes of Health · USThe Ohio State University · US

Funding

IL-2:IL-15 : implications for cancer therapy (Investigator -Initiated Project)ZIASC004002 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WALDMANN, THOMAS · 2009 to 2022
$22.9M
RNA interference-based screens for molecular targets in cancerZIABC011007 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0M
Oncogenic mechanisms and molecular targets in lymphomaZIABC011008 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0M
Clinical development of mechanism-based lymphoma therapiesZIABC011780 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2017 to 2025
$11.4M
Molecular diagnosis and outcome prediction in lymphomaZ01BC011006 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2008 to 2008
$770k
Intramural NIH HHS Z01 BC011006Intramural NIH HHS ZIA BC011008Intramural NIH HHS ZIA BC011780Intramural NIH HHS ZIA SC004002
6 · The paper itself

Abstract

Adult T cell leukemia/lymphoma (ATLL) is a frequently incurable disease associated with the human lymphotropic virus type I (HTLV-I). RNAi screening of ATLL lines revealed that their proliferation depends on BATF3 and IRF4, which cooperatively drive ATLL-specific gene expression. HBZ, the only HTLV-I encoded transcription factor that is expressed in all ATLL cases, binds to an ATLL-specific BATF3 super-enhancer and thereby regulates the expression of BATF3 and its downstream targets, including MYC. Inhibitors of bromodomain-and-extra-terminal-domain (BET) chromatin proteins collapsed the transcriptional network directed by HBZ and BATF3, and were consequently toxic for ATLL cell lines, patient samples, and xenografts. Our study demonstrates that the HTLV-I oncogenic retrovirus exploits a regulatory module that can be attacked therapeutically with BET inhibitors.

Indexed as

Gene Regulatory NetworksAnimalsBasic-Leucine Zipper Transcription FactorsBromodomain Containing ProteinsCell Line, TumorGenes, mycHumansHuman T-lymphotropic virus 1Interferon Regulatory Factor-4Interferon Regulatory FactorsLeukemia-Lymphoma, Adult T-CellMiceProteinsRetroviridae ProteinsBasic-Leucine Zipper Transcription FactorsBATF protein, humanbromodomain and extra-terminal domain protein, humanBromodomain Containing ProteinsHBZ protein, human T-cell leukemia virus type IInterferon Regulatory Factor-4Interferon Regulatory FactorsProteinsRetroviridae ProteinsATLLBATF3BET inhibitorfunctional genomicsHBZ

Identifiers

PMID30057145
PMCPMC8078141
OpenAlexW2882999589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.